Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology

BJU International

Volumn 106, Issue 4, 2010, Pages 462-469

  Droz, Jean Pierre ^a   Balducci, Lodovico ^b   Bolla, Michel ^c   Emberton, Mark ^d   Fitzpatrick, John M ^e   Joniau, Steven ^f   Kattan, Michael W ^g   Monfardini, Silvio ^h   Moul, Judd W ⁱ   Naeim, Arash ^j   Van Poppel, Hendrik ^f   Saad, Fred ^k   Sternberg, Cora N ^l  

^a UNIVERSITÉ LYON 1   (France)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c HÔPITAL MICHALLON   (France)

^d INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h Istituto Palazzolo   (Italy)

ⁱ DUKE UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NOTRE DAME HOSPITAL   (Canada)

^l SAN CAMILLO FORLANINI HOSPITAL   (Italy)

more..

Author keywords

elderly; guidelines; localized disease; metastatic; prostate cancer

Indexed keywords

DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADVANCED CANCER; AGING; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURGERY; COMORBIDITY; DAILY LIFE ACTIVITY; DEVELOPED COUNTRY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELDERLY CARE; EXTERNAL BEAM RADIOTHERAPY; GERIATRICS; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NEUTROPENIA; NUTRITIONAL STATUS; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; AGE; AGED; MALE; NOMOGRAM; PROSTATIC NEOPLASMS;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; HEALTH SERVICES FOR THE AGED; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; NOMOGRAMS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS;

EID: 77953265615     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09334.x     Document Type: Short Survey

References (40)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J Clin 2008 58 : 71 96.
2. Ferlay J, Autier P, Boniol M et al. Estimates of cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18 : 581 592.
3. Ries LAG, Melbert D, Krapcho M et al. eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/1975-2005/, based on December 2009 SEER data submission, posted to the SEER web site 2008. Accessed 19 December 2009
4. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V.2. 2009. Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed December 2009.
6. Thompson I, Trasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007 177 : 2106 2131. (Pubitemid 46726449)
7. Droz J-P, Balducci L, Bolla M et al. Background for the establishment of SIOG Guidelines for the Management of Prostate Cancer in Senior Adults. Crit Rev Oncol Hematol 2010 73 : 68 91
8. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001 285 : 2750 2756.
9. Tewari A, Johnson CC, Divine G et al. Long-term survival probability in men with clinically localized prostate cancer. a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004 171 : 1513 9.
10. Rockwood K, Stadnyk K, MacKnight C et al. A brief clinical instrument to classify frailty in elderly people. Lancet 1999 353 : 205 206.
11. Extermann M, Aapro M, Bernabei R et al. Older cancer patients. Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005 55 : 241 252.
12. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000 36 : 453 471.
13. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968 16 : 622 626.
14. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963 185 : 914 919.
15. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969 9 : 179 186.
16. Blanc-Bisson C, Fonck M, Rainfray M, Soubeyran P, Bourdel-Marchasson I. Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol 2008 67 : 243 254.
17. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000 5 : 224 237. (Pubitemid 30429942)
18. Richstone L, Biancho FJ, Shah HH et al. Radical prostatectomy in men aged 70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008 101 : 541 546.
19. Sun L, Caire AA, Robertson CN et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009 182 : 2242 2249.
20. Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-97. Urology 2001 58 : 977 982.
21. Houterman S, Janssen-Heijnen ML, Verheij CD et al. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis 2006 9 : 179 184.
22. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005 293 : 2095 2101. (Pubitemid 40617061)
23. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 974. (Pubitemid 28445094)
24. D'Amico AV, Moul J, Carroll PR et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003 21 : 2163 2172.
25. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003 21 : 3318 3327. (Pubitemid 46606266)
26. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002 346 : 1138 1144.
27. Zeliadt SB, Potowsky AL, Penson D, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2006 66 : 395 402.
28. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008 299 : 289 295.
29. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent. European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006 24 : 1868 1876.
30. Studer UE, Collette L, Whelan P et al. Using PSA to guide timing of androgen deprivation in patients with T0-4, N0-2, M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008 53 : 941 949.
31. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 164.
32. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 24 : 4448 4456.
33. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007 25 : 2420 2425.
34. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006 175 : 99 103.
35. Mitchell JA, Cooperberg MR, Elkin EP et al. Ability of2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol 2005 173 : 1126 1131.
36. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 26 : 242 245.
37. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 1520.
38. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 1512.
39. Italiano A, Ortholan C, Oudard S et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009 55 : 1368 1376.
40. Droz JP, Chaladaj A. Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU Int 2008 101 (Suppl. 2 23 9.